EA200400007A1 - ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ - Google Patents

ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ

Info

Publication number
EA200400007A1
EA200400007A1 EA200400007A EA200400007A EA200400007A1 EA 200400007 A1 EA200400007 A1 EA 200400007A1 EA 200400007 A EA200400007 A EA 200400007A EA 200400007 A EA200400007 A EA 200400007A EA 200400007 A1 EA200400007 A1 EA 200400007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
propyl
derivatives
norapomorphin
apomorphin
procedures
Prior art date
Application number
EA200400007A
Other languages
English (en)
Other versions
EA008409B1 (ru
Inventor
Хокан Викстрем
Дюрк Дейкстра
Томас Иво Франхискус Хюберт Кремерс
Original Assignee
Аксон Биокемикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аксон Биокемикалс Б.В. filed Critical Аксон Биокемикалс Б.В.
Publication of EA200400007A1 publication Critical patent/EA200400007A1/ru
Publication of EA008409B1 publication Critical patent/EA008409B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описан эффективный фармацевтический состав для лечения заболеваний, выбираемых из группы, состоящей из болезни Паркинсона, синдрома усталых ног, мужской эректильной дисфункции и женской сексуальной дисфункции. Указанный состав включает, как минимум, одно соединение, выбранное из группы, состоящей из апоморфина, 6aR-(-)-N-пропил-норапоморфина, их производных и пролекарств в форме их основания или фармацевтически приемлемых солей или сольватов в качестве активного ингредиента в фармацевтическом пролекарстве, подходящем для перорального/интрадуоденального введения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400007A 2001-06-08 2002-06-07 ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ EA008409B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102036A SE0102036D0 (sv) 2001-06-08 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PCT/SE2002/001106 WO2002100377A1 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF

Publications (2)

Publication Number Publication Date
EA200400007A1 true EA200400007A1 (ru) 2004-04-29
EA008409B1 EA008409B1 (ru) 2007-04-27

Family

ID=20284413

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400007A EA008409B1 (ru) 2001-06-08 2002-06-07 ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ

Country Status (19)

Country Link
US (2) US20040220205A1 (ru)
EP (1) EP1401398A1 (ru)
JP (1) JP2005508865A (ru)
KR (2) KR20090085162A (ru)
CN (1) CN1286451C (ru)
AU (1) AU2002309429B2 (ru)
BR (1) BR0210261A (ru)
CA (1) CA2449571A1 (ru)
CZ (1) CZ20033332A3 (ru)
EA (1) EA008409B1 (ru)
HU (1) HUP0400200A3 (ru)
IL (1) IL158898A0 (ru)
MX (1) MXPA03011314A (ru)
NO (1) NO20035438L (ru)
NZ (1) NZ529623A (ru)
PL (1) PL367883A1 (ru)
SE (1) SE0102036D0 (ru)
WO (1) WO2002100377A1 (ru)
ZA (1) ZA200309048B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US20120196889A1 (en) 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
MX2017008382A (es) * 2014-12-23 2018-04-30 Neuroderm Ltd Formas cristalinas de apomorfina y sus usos.
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
US20180280465A1 (en) 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US20240025857A1 (en) 2020-11-17 2024-01-25 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2025520542A (ja) 2022-06-15 2025-07-03 エバー ニューロ ファーマ ゲーエムベーハー アポモルヒネプロドラッグおよびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
US4120860A (en) * 1977-05-10 1978-10-17 Cooper Lab 3-Aryl-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5222236A (en) * 1988-04-29 1993-06-22 Overdrive Systems, Inc. Multiple integrated document assembly data processing system
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators

Also Published As

Publication number Publication date
CA2449571A1 (en) 2002-12-19
BR0210261A (pt) 2004-07-20
CZ20033332A3 (cs) 2004-12-15
WO2002100377A1 (en) 2002-12-19
SE0102036D0 (sv) 2001-06-08
CN1286451C (zh) 2006-11-29
NO20035438D0 (no) 2003-12-05
MXPA03011314A (es) 2004-12-06
KR20040007644A (ko) 2004-01-24
US20080145417A1 (en) 2008-06-19
HUP0400200A3 (en) 2008-03-28
KR20090085162A (ko) 2009-08-06
ZA200309048B (en) 2004-11-22
CN1531420A (zh) 2004-09-22
AU2002309429B2 (en) 2007-08-09
PL367883A1 (en) 2005-03-07
JP2005508865A (ja) 2005-04-07
HUP0400200A2 (hu) 2004-06-28
EP1401398A1 (en) 2004-03-31
EA008409B1 (ru) 2007-04-27
NO20035438L (no) 2004-02-05
IL158898A0 (en) 2004-05-12
US20040220205A1 (en) 2004-11-04
NZ529623A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
MXPA03005464A (es) Agentes antivirales.
BR0316753A (pt) Método de tratamento para disfunção sexual
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
NZ514574A (en) Novel method of treatment
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
PT1140745E (pt) Derivados de colquinol como agentes de danificacao vascular
ZA200104396B (en) Compositions and methods for stimulating gastrointestinal motility.
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
UA84266C2 (ru) Дозированная врачебная форма в виде таблетки или гранулы для перорального введения, которая содержит ингибитор pde 4 и поливинилпиролидон, способы ее получения и применения
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
EA200400731A1 (ru) Способ и фармацевтическая композиция для непредвиденной контрацепции
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
SE0102440D0 (sv) New compound
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU